This Month's Tiny Gems - June 2012
Cardium Therapeutics, Inc. (CXM)
Cardium Therapeutics is a health sciences and regenerative medicine company focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs that have definable pathways to commercialization, partnering, and other economic monetizations.
Dynavax Technologies Corp. (DVAX)
Dynavax Technologies Corp., a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. The company's lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine designed to provide rapid and earlier protection with fewer doses than currently licensed vaccines.
Idenix Pharmaceuticals, Inc. (IDIX)
Idenix Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and Europe. The company's research and development focus is on the treatment of hepatitis C virus (HCV).
InterMune, Inc. (ITMN)
InterMune, a biotechnology company, engages in the research, development, and commercialization of therapies in pulmonology and orphan fibrotic diseases. ITMN was founded in 1998 and is headquartered in Brisbane, California.